SCHEMBL5832540

SCHEMBL5832540

COc1cc(-c2nc3ccccc3o2)ccc1-c1cccc(N2CCOCC2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.55
HSD17B10 Q99714 3/20 0.49
USP2 O75604 2/20 0.49
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 5/20 0.46
MAPT P10636 5/20 0.46
HPSE Q9Y251 1/20 0.45
HPGD P15428 3/20 0.45
PIM1 P11309 1/20 0.44
PIM3 Q86V86 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
PTGS2 P35354 1/20 0.44
CNR2 P34972 1/20 0.43
HTT P42858 2/20 0.43
AR P10275 1/20 0.42
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 2/20 0.41
PIK3CD O00329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832513 0.83 NPC1 (0.53) NPC1HSD17B10USP2KDM4EALDH1A1
Hydrochloric Acid SCHEMBL5832794 0.82 NPC1 (0.52) NPC1HSD17B10USP2KDM4EALDH1A1
SCHEMBL5831907 0.80 NPC1 (0.65) NPC1HSD17B10USP2KDM4EALDH1A1
SCHEMBL5832256 0.80 NPC1 (0.65) NPC1HSD17B10USP2KDM4EALDH1A1
SCHEMBL5832825 0.79 NPC1 (0.64) NPC1HSD17B10USP2KDM4EALDH1A1
SCHEMBL12956189 0.77 NPC1 (0.79) NPC1HSD17B10USP2KDM4EALDH1A1
Hydrochloric Acid SCHEMBL5831703 0.76 NPC1 (0.65) NPC1HSD17B10USP2KDM4EALDH1A1
SCHEMBL5832759 0.75 NPC1 (0.60) NPC1HSD17B10USP2ALDH1A1SMN1; SMN2
SCHEMBL5831870 0.74 NPC1 (0.62) NPC1HSD17B10USP2KDM4EALDH1A1
SCHEMBL28436509 0.72 NPC1 (1.00) NPC1HSD17B10USP2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885HSD17B10 2509/4885USP2 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.